Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The purpose of this study is to assess the efficacy and the safety of the treatment.
Ovarian Neoplasms
DRUG: docetaxel and cisplatin
Efficacy by response rate according to RECIST criteria and safety, After the 2nd cycle, 4th cycle and 8th cycle and at the follow up period
Time to disease progression or relapse, Until progression througout the study|Survival time, Througout the study|Quality of life based on the questionnaire EORTC QLQ-C30 filled by the patients, Prior to entry, after completion of treatment and at the first follow-up visit
The purpose of this study is to assess the efficacy and the safety of the treatment.